Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 6/20 | 0.33 |
| ▸ | RXRA | P19793 | 6/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.33 |
| ▸ | DDX3X | O00571 | 2/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25584033 | 0.77 | ADRB2 (0.38) | RXRAGRIN1GRIN2B | |
| SCHEMBL25584928 | 0.73 | CACNA2D1 (0.39) | MIFP2RX7RXRAGRIN1GRIN2B | |
| SCHEMBL25920363 | 0.72 | ALK (0.42) | P2RX7RXRAGRIN1GRIN2B | |
| SCHEMBL22839372 | 0.68 | — | — | |
| SCHEMBL25585949 | 0.67 | NOTUM (0.37) | P2RX7RXRAGRIN1GRIN2B | |
| SCHEMBL4450758 | 0.62 | TAS1R3 (0.45) | — | |
| SCHEMBL17795447 | 0.62 | MIF (0.58) | MIFP2RX7DDX3XSPHK1 | |
| SCHEMBL20794423 | 0.61 | TLR2 (0.49) | — | |
| SCHEMBL18844905 | 0.61 | TLR2 (0.49) | — | |
| SCHEMBL16479597 | 0.60 | MIF (0.59) | MIFP2RX7DDX3XSPHK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | FUT6, DDOST, MGAM | MIF 3018/4885P2RX7 2953/4885GBA1 43/4885 |
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | FUT6, DDOST, MGAM | MIF 3018/4885P2RX7 2953/4885GBA1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.